metabolism. Use Caution/Monitor.dabrafenibMonitor Closely (1)dabrafenib will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.darifenacinMonitor Closely (2)darifenacin will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. darifenacin and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.darunavirMonitor Closely (1)darunavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dasatinibMonitor Closely (2)dasatinib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. dasatinib and solifenacin both increase QTc interval. Use Caution/Monitor.degarelixMonitor Closely (1)degarelix and solifenacin both increase QTc interval. Use Caution/Monitor.desfluraneSerious - Use Alternative (1)desflurane and solifenacin both increase QTc interval. Avoid or Use Alternate Drug.desipramineMonitor Closely (2)solifenacin and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. solifenacin and desipramine both increase QTc interval. Use Caution/Monitor.deutetrabenazineMonitor Closely (1)deutetrabenazine and solifenacin both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexamethasoneMonitor Closely (1)dexamethasone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.DHEA, herbalMonitor Closely (1)DHEA, herbal will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dicyclomineMonitor Closely (1)dicyclomine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.diltiazemMonitor Closely (1)diltiazem will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.dimenhydrinateMinor (1)dimenhydrinate increases toxicity of solifenacin by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.diphenhydramineMonitor Closely (1)diphenhydramine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.disopyramideMonitor Closely (1)solifenacin and disopyramide both increase QTc interval. Use Caution/Monitor.dofetilideSerious - Use Alternative (1)dofetilide increases toxicity of solifenacin by QTc interval. Avoid or Use Alternate Drug.dolasetronMonitor Closely (1)dolasetron and solifenacin both increase QTc interval. Use Caution/Monitor.donepezilMonitor Closely (1)donepezil increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)donepezil and solifenacin both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)donepezil decreases effects of solifenacin by pharmacodynamic antagonism. Minor/Significance Unknown.donepezil transdermalMonitor Closely (1)donepezil transdermal, solifenacin. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dosulepinMonitor Closely (1)solifenacin and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepinMonitor Closely (2)solifenacin and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor. doxepin and solifenacin both increase QTc interval. Use Caution/Monitor.dronedaroneContraindicated (1)solifenacin and dronedarone both increase QTc interval. Contraindicated.Monitor Closely (1)dronedarone will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.droperidolMonitor Closely (3)solifenacin decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. solifenacin decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. droperidol increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Serious - Use Alternative (1)solifenacin and droperidol both increase QTc interval. Avoid or Use Alternate Drug.duvelisibMonitor Closely (1)duvelisib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.echothiophate iodideMonitor Closely (1)echothiophate iodide increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.efavirenzMonitor Closely (2)efavirenz will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. efavirenz and solifenacin both increase QTc interval. Use Caution/Monitor.elagolixMonitor Closely (1)elagolix decreases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eliglustatSerious - Use Alternative (1)solifenacin and eliglustat both increase QTc interval. Avoid or Use Alternate Drug.elvitegravir/cobicistat/emtricitabine/tenofovir DFMonitor Closely (1)elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.encorafenibMonitor Closely (1)encorafenib, solifenacin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.Serious - Use Alternative (1)encorafenib and solifenacin both increase QTc interval. Avoid or Use Alternate Drug.entrectinibSerious - Use Alternative (1)entrectinib and solifenacin both increase QTc interval. Avoid or Use Alternate Drug.enzalutamideMonitor Closely (1)enzalutamide will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.eribulinSerious - Use Alternative (1)eribulin and solifenacin both increase QTc interval. Avoid or Use Alternate Drug.erythromycin baseSerious - Use Alternative (2)erythromycin base will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. solifenacin and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateSerious - Use Alternative (2)erythromycin ethylsuccinate will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. solifenacin and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateSerious - Use Alternative (2)erythromycin lactobionate will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. solifenacin and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateSerious - Use Alternative (2)erythromycin stearate will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. solifenacin and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.escitalopramMonitor Closely (1)escitalopram increases toxicity of solifenacin by QTc interval. Use Caution/Monitor.eslicarbazepine acetateMonitor Closely (1)eslicarbazepine acetate will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.etravirineMonitor Closely (1)etravirine will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fedratinibMonitor Closely (1)fedratinib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fesoterodineMonitor Closely (1)fesoterodine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.fexinidazoleSerious - Use Alternative (2)fexinidazole and solifenacin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval. fexinidazole will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fingolimodMonitor Closely (1)fingolimod and solifenacin both increase QTc interval. Use Caution/Monitor.flavoxateMonitor Closely (1)flavoxate and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.flecainideMonitor Closely (1)solifenacin and flecainide both increase QTc interval. Use Caution/Monitor.fluconazoleContraindicated (1)solifenacin and fluconazole both increase QTc interval. Contraindicated.Monitor Closely (1)fluconazole will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fludrocortisoneMonitor Closely (1)fludrocortisone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fluoxetineMonitor Closely (1)solifenacin and fluoxetine both increase QTc interval. Use Caution/Monitor.fluphenazineMonitor Closely (4)solifenacin decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. solifenacin decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor. fluphenazine increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. solifenacin and fluphenazine both increase QTc interval. Use Caution/Monitor.fluvoxamineMonitor Closely (2)fluvoxamine will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. solifenacin and fluvoxamine both increase QTc interval. Use Caution/Monitor.fosamprenavirMonitor Closely (1)fosamprenavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fosaprepitantMonitor Closely (1)fosaprepitant will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.foscarnetSerious - Use Alternative (1)solifenacin and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.fosphenytoinMonitor Closely (1)fosphenytoin will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.fostemsavirMonitor Closely (1)solifenacin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.galantamineMonitor Closely (1)galantamine increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Minor (1)galantamine decreases effects of solifenacin by pharmacodynamic antagonism. Minor/Significance Unknown.gemifloxacinMonitor Closely (1)gemifloxacin and solifenacin both increase QTc interval. Use Caution/Monitor.gemtuzumabMonitor Closely (1)solifenacin and gemtuzumab both increase QTc interval. Use Caution/Monitor.gilteritinibMonitor Closely (1)gilteritinib and solifenacin both increase QTc interval. Use Caution/Monitor.glasdegibSerious - Use Alternative (1)solifenacin and glasdegib both increase QTc interval. Avoid or Use Alternate Drug.glycopyrrolateMonitor Closely (1)glycopyrrolate and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrrolate inhaledMonitor Closely (1)glycopyrrolate inhaled and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrronium tosylate topicalSerious - Use Alternative (1)glycopyrronium tosylate topical, solifenacin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.goserelinMonitor Closely (1)solifenacin and goserelin both increase QTc interval. Use Caution/Monitor.granisetronMonitor Closely (1)granisetron and solifenacin both increase QTc interval. Use Caution/Monitor.grapefruitMonitor Closely (1)grapefruit will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.griseofulvinMonitor Closely (1)griseofulvin will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.haloperidolMonitor Closely (4)solifenacin decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. solifenacin decreases levels of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. haloperidol increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. haloperidol and solifenacin both increase QTc interval. Use Caution/Monitor.henbaneMonitor Closely (1)henbane and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.histrelinMonitor Closely (1)solifenacin and histrelin both increase QTc interval. Use Caution/Monitor.homatropineMonitor Closely (1)homatropine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine AMonitor Closely (1)huperzine A increases and solifenacin decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocortisoneMonitor Closely (1)hydrocortisone will decrease the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.hydroxychloroquine sulfateSerious - Use Alternative (1)hydroxychloroquine sulfate and solifenacin both increase QTc interval. Avoid or Use Alternate Drug.hydroxyzineMonitor Closely (1)hydroxyzine and solifenacin both increase QTc interval. Use Caution/Monitor.hyoscyamineMonitor Closely (1)hyoscyamine and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayMonitor Closely (1)hyoscyamine spray and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.ibutilideSerious - Use Alternative (1)solifenacin and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.idelalisibSerious - Use Alternative (1)idelalisib will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesiloperidoneMonitor Closely (4)solifenacin decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. solifenacin decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor. iloperidone increases effects of solifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. iloperidone increases levels of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.Serious - Use Alternative (1)solifenacin and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.imipramineMonitor Closely (2)solifenacin and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. solifenacin and imipramine both increase QTc interval. Use Caution/Monitor.indinavirMonitor Closely (1)indinavir will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.inotuzumabSerious - Use Alternative (1)solifenacin and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug.ipratropiumMonitor Closely (1)ipratropium and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isofluraneSerious - Use Alternative (1)isoflurane and solifenacin both increase QTc interval. Avoid or Use Alternate Drug.isoniazidMonitor Closely (1)isoniazid will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.istradefyllineMonitor Closely (1)istradefylline will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.itraconazoleContraindicated (1)itraconazole will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration in patients with renal or hepatic impairment may result in increased solifenacin levels and